Patent ID: 7714110

Claim:
A fusion molecule comprising: a first portion that targets cells bearing the OX-2/CD200 antigen, wherein the first portion is an anti-CD200 antibody or antigen-binding fragment thereof that binds to CD200 comprising (i) a light chain CDR1 having the sequence set forth in residues 26-36 of SEQ ID NO: 208, (ii) a light chain CDR2 having the sequence set forth in residues 52-58 of SEQ ID NO: 208, (iii) a light chain CDR3 having the sequence set forth in residues 91-99 of SEQ ID NO: 208, (iv) a heavy chain CDR1 having the sequence set forth in SEQ ID NO: 114, (v) a heavy chain CDR2 having the sequence set forth in SEQ ID NO: 165, and (vi) a heavy chain CDR3 having the sequence set forth in SEQ ID NO: 189; and a second portion that promotes the death of cells, wherein the second portion is a toxin.